📰 Double Blind Phase News
Page 2 - Double Blind Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Double Blind Phase. Real-time updates on events, politics, business and more.
September 12, 2021
AUA 2021 First and Second Line Therapy in Advanced and Metastatic Bladder Cancer, metastatic urothelial cancer, MVAC chemotherapy, checkpoint immunotherapy, platinum-refractory advanced UC, Keynote-045 study, IMvigor130 trial, DANUBE trial, KEYNOTE-361 trial.
May 4, 2021
Share this article Share this article ZUG, Switzerland, May 4, 2021 /PRNewswire/ -- Quercis Pharma AG, a private, clinical stage biopharmaceutical company leveraging its novel antithrombotic platform, today announces that it has entered into a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the protocol titled, "A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Isoquercetin on Thromboembo...
April 20, 2021
Message : Required fields Stockholm April 20, 2021 - BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimers Disease with Lecanemab, an Anti-Aβ Protofibril Antibody, in the peer-reviewed journal Alzheimers Research & Therapy. The manuscript describes results from Study 201, a Phase 2b proof-of-concept study that explored the impact of treatment w...
April 20, 2021
Share this article Share this article STOCKHOLM, April 20, 2021 /PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimers Disease with Lecanemab, an Anti-Aβ Protofibril Antibody, in the peer-reviewed journal Alzheimers Research & Therapy. The manuscript describes results from Study 201, a Phase 2b proof-of-concept study that explored the i...